Authors: MICHAEL M OZA A EGORIN MJ PATNAIK A FIRBY P SIU LL LITCHMAN M MOORE MJ

Citation: M. Michael et al., PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) ANALYSIS OF A PHASE-I STUDY OF TAXOL((R))(T), CARBOPLATIN (C) WITH P-GLYCOPROTEIN (P-GP) MODULATOR PSC-833 (PSC), Annals of oncology, 9, 1998, pp. 621-621

Authors: MOORE MJ FELD R HEDLEY D OZA A SIU LL

Citation: Mj. Moore et al., A PHASE-II STUDY OF TEMOZOLOMIDE IN ADVANCED UNTREATED PANCREATIC-CANCER, Investigational new drugs, 16(1), 1998, pp. 77-79

Authors: ORTEGA A DRANITSARIS G STURGEON J SUTHERLAND H OZA A

Citation: A. Ortega et al., COST-UTILITY ANALYSIS OF PACLITAXEL IN COMBINATION WITH CISPLATIN FORPATIENTS WITH ADVANCED OVARIAN-CANCER, Gynecologic oncology, 66(3), 1997, pp. 454-463

Authors: CHART H FROST JA OZA A THWAITES R GILLANDERS S

Citation: H. Chart et al., HEAT-STABLE SEROTYPING ANTIGENS EXPRESSED BY STRAINS OF CAMPYLOBACTER-JEJUNI ARE PROBABLY CAPSULAR AND NOT LONG-CHAIN LIPOPOLYSACCHARIDE, Journal of Applied Bacteriology, 81(6), 1996, pp. 635-640

Authors: RADFORD JA CROWTHER D ROHATINER AZS RYDER WDJ GUPTA RK OZA A DEAKIN DP ARNOTT S WILKINSON PM JAMES RD JOHNSON RJ LISTER TA

Citation: Ja. Radford et al., RESULTS OF A RANDOMIZED TRIAL COMPARING MVPP CHEMOTHERAPY WITH A HYBRID REGIMEN, CHLVPP EVA, IN THE INITIAL TREATMENT OF HODGKINS-DISEASE/, Journal of clinical oncology, 13(9), 1995, pp. 2379-2385